Lilly invests $2.5B in new German site to boost tirzepatide supply, $100M for local biotechs
Eli Lilly is set to build a new $2.5 billion facility in Germany to increase manufacturing capacity for its blockbuster diabetes and obesity drugs, and the pharma giant also announced Friday it will spend up to $100 million on local biotechs.
The facility will be located in Alzey, which is about an hour drive from Frankfurt. It’s expected to boost the company’s injectable production as well as its device manufacturing capabilities and, ultimately, increase Lilly’s incretin supply. Lilly’s blockbuster drug tirzepatide — approved as Mounjaro for type 2 diabetes and Zepbound for obesity — targets GIP and GLP-1 receptors, which are naturally activated by incretin hormones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.